News ReleaseView printer-friendly version
Quidel *Fourth Quarter Conference Call Alert
Annual Shareholders' Meeting Date Set
SAN DIEGO, Jan. 23 /PRNewswire-FirstCall/ -- Quidel Corporation (Nasdaq: QDEL), a leading provider of rapid point-of-care (POC) diagnostic tests, today announced that it will release 2001 fourth quarter results after market close on Tuesday, February 12, at 4:10 p.m. Eastern Time (1:10 p.m. Pacific Time).
S. Wayne Kay, President and Chief Executive Officer, and Paul E. Landers, Vice President and Chief Financial Officer, will be hosting an investment-community conference call beginning at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time) on Tuesday, February 12, 2002 to discuss those results and to answer questions.
Individuals interested in participating in the conference call may do so by calling (888) 882-0109 from the U.S., or for international callers (212) 346-0333.
Those interested in listening to the conference call live via the Internet may do so by visiting the Company's Website at www.quidel.com . To listen to the live call, please go to the Web site 15 minutes prior to its start to register, download, and install the necessary audio software.
A replay will be available on Quidel's Web site for 14 days. A telephone replay will also be available for 48 hours following the conclusion of the call by dialing (800) 633-8284, or (858) 812-6440, and entering reservation number 20274063.
Quidel will hold its 2002 Annual Shareholders' Meeting on May 21, at 10:30 a.m. PT. The meeting will be held at:
Del Mar Marriott Hotel
11966 El Camino Real
San Diego, CA 92130
Quidel Corporation discovers, develops, manufactures and markets rapid point-of-care diagnostic tests for detection of medical conditions and illnesses. These products provide accurate, rapid and cost-effective diagnostic information for acute and chronic conditions associated with women's health, in areas such as reproduction and diseases of the elderly. Quidel also provides point-of-care diagnostics for infectious diseases, including influenza A and B, strep throat, H. pylori infection, chlamydia, infectious mononucleosis and bacterial vaginosis. Quidel's products are sold to healthcare professionals for use in physicians' offices, clinical laboratories and pharmacies, and to consumers through organizations that provide private label, store brand products. These tests provide diagnostic information to enable rapid treatment and improve health outcomes, lower costs and increase patient satisfaction. For more information, please visit Quidel's Web site at www.quidel.com .
SOURCE Quidel Corporation
CONTACT: Bruce Voss, firstname.lastname@example.org, or Martin Halsall, email@example.com, of Lippert/Heilshorn & Associates, +1-310-691-7100, for Quidel Corporation; or Andrea Wasilew, Manager of Investor Relations, +1-858-552-7955, firstname.lastname@example.org, or Paul E. Landers, Vice President & CFO, +1-858-552-7962, both of Quidel Corporation/